360 related articles for article (PubMed ID: 26999067)
1. An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.
Durlacher CT; Li ZL; Chen XW; He ZX; Zhou SF
Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):585-601. PubMed ID: 26999067
[TBL] [Abstract][Full Text] [Related]
2. Aurora kinase A inhibitors: promising agents in antitumoral therapy.
Malumbres M; Pérez de Castro I
Expert Opin Ther Targets; 2014 Dec; 18(12):1377-93. PubMed ID: 25200357
[TBL] [Abstract][Full Text] [Related]
3. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of mitotic interaction between the nucleoporin Tpr and aurora kinase A.
Kobayashi A; Hashizume C; Dowaki T; Wong RW
Cell Cycle; 2015; 14(9):1447-58. PubMed ID: 25789545
[TBL] [Abstract][Full Text] [Related]
7. Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.
Venkatakrishnan K; Zhou X; Ecsedy J; Mould DR; Liu H; Danaee H; Fingert H; Kleinfield R; Milton A
J Clin Pharmacol; 2015 Mar; 55(3):336-47. PubMed ID: 25302940
[TBL] [Abstract][Full Text] [Related]
8. Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors.
Liewer S; Huddleston A
Expert Opin Investig Drugs; 2018 Jan; 27(1):105-112. PubMed ID: 29260599
[TBL] [Abstract][Full Text] [Related]
9. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Falchook GS; Venkatakrishnan K; Sarantopoulos J; Kurzrock R; Mita AC; Fu S; Mita MM; Zhou X; Jung JA; Ullmann CD; Milch C; Rosen LS
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):563-72. PubMed ID: 26073352
[TBL] [Abstract][Full Text] [Related]
10. Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data.
Tayyar Y; Jubair L; Fallaha S; McMillan NAJ
Crit Rev Oncol Hematol; 2017 Nov; 119():59-65. PubMed ID: 29065986
[TBL] [Abstract][Full Text] [Related]
11. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.
Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B
Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439
[TBL] [Abstract][Full Text] [Related]
12. Genetic Interactions between the Aurora Kinases Reveal New Requirements for AURKB and AURKC during Oocyte Meiosis.
Nguyen AL; Drutovic D; Vazquez BN; El Yakoubi W; Gentilello AS; Malumbres M; Solc P; Schindler K
Curr Biol; 2018 Nov; 28(21):3458-3468.e5. PubMed ID: 30415701
[TBL] [Abstract][Full Text] [Related]
13. Modulation of oxidative phosphorylation augments antineoplastic activity of mitotic aurora kinase inhibition.
Zhang Z; Zeng D; Zhang W; Chen A; Lei J; Liu F; Deng B; Zhuo J; He B; Yan M; Lei X; Wang S; Lam EW; Liu Q; Wang Z
Cell Death Dis; 2021 Sep; 12(10):893. PubMed ID: 34593753
[TBL] [Abstract][Full Text] [Related]
14. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
Do TV; Xiao F; Bickel LE; Klein-Szanto AJ; Pathak HB; Hua X; Howe C; O'Brien SW; Maglaty M; Ecsedy JA; Litwin S; Golemis EA; Schilder RJ; Godwin AK; Connolly DC
Oncogene; 2014 Jan; 33(5):539-49. PubMed ID: 23334327
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.
Zhou X; Lockhart AC; Fu S; Nemunaitis J; Sarantopoulos J; Muehler A; Rangachari L; Bargfrede M; Venkatakrishnan K
J Clin Pharmacol; 2019 Sep; 59(9):1204-1215. PubMed ID: 30985952
[TBL] [Abstract][Full Text] [Related]
16. Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
Zullo KM; Guo Y; Cooke L; Jirau-Serrano X; Mangone M; Scotto L; Amengual JE; Mao Y; Nandakumar R; Cremers S; Duong J; Mahadevan D; O'Connor OA
Clin Cancer Res; 2015 Sep; 21(18):4097-109. PubMed ID: 25878331
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
[TBL] [Abstract][Full Text] [Related]
18. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
[TBL] [Abstract][Full Text] [Related]
19. The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells.
Zumbar CT; Usubalieva A; King PD; Li X; Mifsud CS; Dalton HM; Sak M; Urio S; Bryant WM; McElroy JP; Farmer G; Lehman NL
J Neurooncol; 2018 May; 137(3):481-492. PubMed ID: 29396807
[TBL] [Abstract][Full Text] [Related]
20. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Alrifai D; Pettengell R
Expert Opin Investig Drugs; 2014 Dec; 23(12):1731-6. PubMed ID: 25323772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
